Arsenic trioxide (ATO) is presently the most active single agent in the treatment of acute promyelocytic leukemia (APL). This review provides insights into the mode of action and the pharmacological properties of ATO, and summarizes the most relevant results of more than 20 treatment studies in relapsed or newly diagnosed APL published between 1997 and 2011. ATO acts by targeting multiple pathways in APL leading to apoptosis and myeloid differentiation. It induces complete remission without myelosuppression and causes only few adverse effects. In relapsed APL, ATO-based salvage therapy has been able to induce long-lasting remissions and possible cure in 50-81% of patients. In newly diagnosed APL, two main strategies are currently pursued. ATO is either included into induction therapy with the aim to minimize or eliminate chemotherapy, or it is incorporated as an additive into established first-line concepts with all-trans-retinoic acid and chemotherapy to reinforce their anti-leukemic efficacy. Recent results suggest a high efficacy of ATO in both concepts. In conclusion, experimental research and clinical studies have made contributions toward a better understanding of the molecular mechanisms induced by ATO in APL cells and have established this historic substance as an important candidate for the further improvement of APL therapy.
Introduction
Acute promyelocytic leukemia (APL) accounts for approximately 5-10% of cases of acute myeloid leukemia (AML). It can be differentiated from all other forms of AML by its characteristic morphology (AML FAB M3/M3v) and the presence of the diseasedefining chromosomal translocation t (15;17) leading to a fusion between the genes promyelocytic leukemia (PML) and the retinoic acid receptor-a (RARa). The PML-RARa fusion product disturbs the cellular signaling of wild-type RARa in myeloid progenitor cells, which results in a differentiation block at the promyelocyte stage. 1, 2 In rare genetic variants of APL, other genes than PML are fused with the RARa-gene, for example, PLZF-RARa as result of t (11;17) . 3 Clinically, APL stands out by frequently presenting with coagulation disorders, which are associated with life-threatening hemorrhages. This complication is one of the most frequent causes of early deaths (EDs) in the time around initial diagnosis and beginning of treatment. 4 All-trans-retinoic acid (ATRA) specifically targets the molecular defect PML-RARa and thereby resolves the maturation arrest induced by this fusion protein. 5, 6 Since its introduction in the early 1990s, cure rates of up to 80% in APL have been achieved by the application of regimen containing ATRA and anthracycline-based chemotherapy. However, up to 10% of patients treated in clinical studies die during induction therapy and up to 15% experience a relapse. A reduction of EDs and relapses are therefore important goals of efforts to further improve the prognosis of APL patients. 7, 8 In the case of relapse, a second remission can be achieved in approximately 90% of patients with the use of intensive chemotherapy ( ± ATRA). In most of these cases, remissions are not durable and subsequent allogeneic or autologous stem cell transplantation is recommended. [9] [10] [11] However, the toxicity associated with the salvage chemotherapy was reported to be an important reason for a relatively high rate of patients not qualifying for transplantation and for considerable transplantation -related mortality. 10 Arsenic derivatives have been used for treatment of malignant and inflammatory diseases for over 2000 years in Chinese medicine. In European and American literature, attention to the effectiveness of arsenic in leukemia was drawn for the first time in 1882. 12, 13 Arsenic trioxide (ATO) was approved for the treatment of relapsed and refractory APL in Europe in March 2002. More recent data have shown ATO to be effective in the primary therapy of APL as a single agent with curative potential. 14, 15 Here, we provide an overview of the current role of ATO in the treatment of adult patients with APL.
Pharmacological properties of ATO

Mechanism of action
The efficacy of arsenic derivatives in neoplasia is based on several modes of action: Induction of differentiation and apoptosis, inhibition of proliferation and antiangiogenic effects. 16, 17 Although the understanding of the cellular pathomechanisms of APL has advanced considerably in the last decades, the molecular mechanisms induced by arsenic in APL cells remain largely elusive. In vitro studies have shown a dosedependent dual effect of ATO in APL, whereby higher concentrations (0.5À2.0 mmol/l) induced apoptosis and lower concentrations (0.1À0.5 mmol/l) induced partial differentiation of APL cells. The rapid degradation of PML-RARa proteins, which was induced by ATO at 0.1-2.0 mmol/l, could contribute to both effects. 18, 19 ATO-induced apoptosis is mediated by the activation of caspases, 16, 20 which may be attributed to genomic instability caused by the ATO-mediated downregulation of the human telomerase gene (HTERT). 21 The antiangiogenic effect of ATO in solid tumors, and possibly also leukemia, may be associated with the downregulation of vascular endothelial growth factor, with subsequent apoptosis of endothelial cells, leading to reduced vascularization. 22 Recent ex vivo and in vitro studies of APL strongly support an important role of the self-renewal capacity of leukemia-initiating cells for the persistence of the disease. Murine APL models suggest that treatment with ATO as opposed to ATRA results in the eradication of these leukemia-initiating cells, thereby inducing effective remissions and possible cure. 17 Resistances against ATO have been observed in a small proportion of cases. Considering the complex mechanism of action, resistance might be due to various reasons. Very recently, missense mutations in the PML-RARa transcripts, resulting in A216V and L218P substitutions in the PML B2 domain, were identified in two patients who were clinically resistant to ATO. 23 As the B2 domain is thought to be critical for binding of ATO, mutations in this domain may have an important role in the mechanism of resistance. 23 
Pharmacokinetics
Arsenic is quickly absorbed in the gastrointestinal tract following oral administration. As 95À97% of arsenic in the blood is bound to hemoglobin, it quickly distributes through the body. It is stored preferentially in tissues that are rich in sulfhydryl groupcontaining proteins such as hair and nails, but also in other organs such as liver, lung, heart muscle and kidneys. 24 Plasma pharmacokinetics analyzed in patients at the fist day of therapy showed that plasma levels of arsenic fall quickly after intravenous administration and had a terminal half-life of 12 ± 3 h. Comparison of the pharmacokinetic parameters in patients between days 1 and 30 of remission induction therapy showed that continuous administration of ATO did not alter its pharmacokinetics and did not lead to accumulation in the plasma. 24 Trivalent arsenic compounds such as ATO are predominantly methylated in the body and excreted through the kidneys. 25 Measurements of ATO metabolites in urine have led to differing results across several studies, ranging from 1-8 to 19% or 32À65%. [24] [25] [26] [27] Independently of this unexplained broad range, the results indicate that other elimination mechanisms, such as bile and feces, must have a role in the excretion of high arsenic doses. In a study of adult cancer patients with varying degrees of renal dysfunction, systemic exposure of arsenic and its methylated metabolites following standard dosing of ATO was increased. In case of severe renal dysfunction, the safety profile of ATO was not affected significantly using a dose-reduced schedule. 28 There are publications, which provide evidence that ATO crosses the blood-brain barrier after intravenous or oral application. The concentration of arsenic in the cerebrospinal fluid correlates well with the plasma level, reaching up to 14 to 20-30% of plasma levels in patients treated with ATO intravenously and 18% in patients receiving oral formulation of ATO. [29] [30] [31] [32] Interactions with other substances Synergistic actions between ATO and other substances have been described. Combined with ATRA, a remarkable intensification of anti-leukemic effects was observed in vitro and in vivo. [33] [34] [35] [36] Cooperating effects of these two substances have been shown in vitro in HL-60 cells, in which treatment with ATRA led to an upregulation of the transmembrane protein aquaglyceroporin-9, 37 which in turn is involved in the uptake of arsenic. Experiments studying the combined effects of ATRA and ATO in NB4 cells by integrating cDNA microarray technology and two-dimensional gel electrophoresis suggested a complex cooperating network of factors involved in granulocytic differentiation. 38 These results point to different mechanisms of action of the two drugs and indicate that ATRA exerts its effects mainly through nuclear receptor-mediated transcriptional regulation, whereas ATO exercises its effects by targeting multiple pathways/cascades, with emphasis on the transcriptome and proteome level. Through these different mechanisms of action, the two substances complement each other. 38 Apart from cooperating effects with ATRA, it could be shown that sensitivity to ATO could be increased by modulation of the glutathione redox system. In vitro treatment of NB4 cells with ascorbic acid was able to reduce intracellular glutathione levels and thereby selectively sensitize leukemic cells to ATO. [39] [40] [41] Besides positive drug combinations, the adverse effects of ATO may be also enhanced by other substances. The mechanisms underlying the cardiotoxic effects of ATO are unclear. In clinical practice it is important to know that ATO can lengthen the QT time interval, and this effect may be intensified by other drugs. 26, 42 Clinical results of ATO in patients with APL
ATO in relapsed APL
The first reports on the successful treatment of APL with arsenic derivatives came from China and were initiated in the early 1990s. In a study of 242 cases, the complete remission (CR) rate in newly diagnosed and relapsed APL was 88% and 60%, respectively. 43 In 136 patients who underwent further observation, the survival probability after 5 years was 92 and 77% after 7 years. 43 Based on the Chinese experience, ATO was introduced in the treatment of patients with relapsed or refractory APL in Europe and the United States.
Treatment concepts in relapsed APL. The treatment concepts of 14 studies with ATO in relapsed APL published between 1997 and 2011 are summarized in Table 1 . The studies were conducted as single-arm, short-time studies to evaluate the efficacy and safety of ATO monotherapy for remission induction in relapsed APL. There was one small randomized study of 20 patients comparing ATO with ATO þ ATRA. 51 In total, 304 patients with first or later relapse of APL were evaluated in these trials. In the earlier studies, induction therapy comprised a fixed ATO dose of 10 mg/day intravenously. In later studies, the ATO dose was 0.15 mg/kg of body weight/day, which is currently still in use. In most trials ATO was administered until CR was achieved or up to a maximum of 60 days (Table 1) . Additional chemotherapy (mostly anthracyclines or hydroxyurea) was administered during induction therapy, if there were rapid increases of leukocyte counts (410 Â 10 9 /l) or in the event of APL differentiation syndrome.
Post-induction therapy differed considerably between studies (Table 1) . It comprised up to five ATO courses, each lasting 28 days in most studies, and was often combined with chemotherapy (mostly anthracyclines/cytosine arabinoside (Ara-C)) and sometimes with ATRA. In total, 59 patients included in these studies proceeded to autologous or allogeneic stem cell transplants after achieving ATO-induced remission.
Results in relapsed APL. Of the 304 relapsed APL patients treated within the above-specified studies, 301 cases had a hematological relapse and three patients had a molecular relapse. Of note, approximately 40% of these patients were already in their second or more advanced relapse upon entry into the study. The clinical outcomes of the patients are summarized in Table 2 . Remission rates varied between 73
Arsenic trioxide in the treatment of acute promyelocytic leukemia E Lengfelder et al and 100%. Overall, 86% of the 304 patients achieved complete hematological remission (CR). In 7% of the patients, the administered therapy did not induce an adequate response and 7% of patients died during induction therapy. The median time to remission varied from 30 to 59 days across the studies.
There was a great variability of the molecular remission rates possibly because of the different time of the molecular assessment after the start of therapy (Table 2 ). In the largest series, the reported rate of molecular remission was 86% after two ATO courses. 44 Parameters with negative influence on the remission duration were a higher pre-treatment WBC count (above 10 Â 10 9 /l; P ¼ 0.038) and subsequent relapse after the first relapse. 45, 57, 58 The survival probability after 2 years ranged between 50 and 81%.
Owing to the rarity of APL relapses, no randomized studies have been conducted so far to compare the different postremission strategies after ATO. Follow-up data have so far only been available from retrospective analyses of patients who received ATO±various combinations of ATRA and chemotherapy ± hematopoietic stem cell transplantation. Owing to this heterogeneity and the small numbers of patients analyzed, the obtained results remain difficult to assess.
In approaches without transplantation, there was some evidence that remission duration was longer when combinations of ATO with either ATRA or chemotherapy, or with both, were used as compared with chemotherapy or ATO alone. 45, 57, 58 In a small series of patients, prolonged postremission therapy over 28 weeks consisting of four courses of Randomization between ATO and ATO plus ATRA. Patients n After consolidation.
Arsenic trioxide in the treatment of acute promyelocytic leukemia E Lengfelder et al ATO and seven shorter courses of ATRA induced long-lasting molecular remissions in 88% of patients, with a median remission duration of 25 months (range 11-50). 59 For treatment concepts including transplantation, updated results of a pivotal US multicenter trial suggested an advantage of transplantation (allogeneic or autologous) as compared with no further therapy. 57, 58 In an Indian series of 37 relapsed APL patients, which included patients treated with ATO or the conventional ATRA-plus-chemotherapy regimen for first-line therapy, autologous transplantation was superior to ATO plus ATRA. After a median follow-up of 33 months, the estimated 5-year overall survival (OS) was 100% for transplanted patients versus 39% for patients treated with ATO and ATRA. 60 There are only little data available on the role of allogeneic transplantation in relapsed APL. In a report of 54 Chinese patients in second remission, the OS after 2 years was 82% for ATO-treated patients as compared with 43% for patients having received allogeneic transplantation, which may be attributed to a high treatment-related mortality. 61 For relapses after allogeneic transplantation, prolonged molecular remissions have been reported for combination regimen containing ATO and ATRA. 62 
Management of CNS relapse
Extramedullary relapse in APL is a rare event, occurring in less than 5% of APL patients treated with an ATRA-plus-chemotherapy -based regimen. When it does occur, it predominantly presents in the CNS and is frequently associated with concomitant bone marrow relapse. 63, 64 For CNS relapse, intrathecal chemotherapy with methotrexate and Ara-C ( ± corticosteroids) with or without subsequent irradiation in combination with systemic application of ATO represents an effective salvage regimen, which is able to induce stable remissions. 32, 65, 66 As CNS relapses were also observed after ATO salvage therapy, the prophylactic administration of intrathecal chemotherapy might reduce the risk of later CNS relapse. 67 
ATO in newly diagnosed APL
After the excellent results achieved by ATO in patients with relapse, its efficacy has also been investigated in newly diagnosed APL. Thereby two different strategies have been pursued. One approach has the aim to minimize or even eliminate cytotoxic chemotherapy from induction and consolidation regimen by substituting it through ATO. The other concept aims to reinforce the anti-leukemic efficacy of the standard ATRA-plus-chemotherapy-based regimen by adding ATO.
Treatment concepts in newly diagnosed APL. A synopsis of trials for an evaluation of ATO-based induction and consolidation regimen is shown in Table 3 . These studies were primarily performed to investigate the short-term efficacy and safety of ATO in newly diagnosed APL.
In two non-comparative prospective studies conducted in India and Iran, ATO monotherapy was administered for remission induction and prolonged consolidation or maintenance therapy. 14, 15 Both of these studies were recently updated and corroborate a long-term efficacy of ATO in APL. 70, 71 In the report by Mathews et al. 71 (India), ATO consolidation and maintenance therapy consisted of one 4-week consolidation course followed by six courses of ATO for 10 days every month. In the study by Ghavamzadeh et al. 70 (Iran), patients primarily received one consolidation course of ATO. This was later expanded to four courses, with delayed application of the third and fourth courses, which were administered 1 and 2 years after the second consolidation course (Table 3) . 70 Both of these studies also included a small proportion of children.
Another trial conducted at the MD Anderson Cancer Center combined ATO with ATRA, which was extended with gemtuzumab ozogamicin, and in some cases with idarubicin when patients presented with an initial WBC count above 10 Â 10 9 /l. Initial results gained from 44 cases were later confirmed by expanding the cohort to 81 patients. 68, 69 The only randomized study of 61 patients was conducted in China. In this study, three induction regimen were compared: ATO monotherapy, ATO plus ATRA (reduced to 25 mg/m 2 /day) and ATRA monotherapy (45 mg/m 2 /day), each followed by consolidation with chemo-and maintenance therapy. 35 Owing to its superiority, only the combined treatment arm was continued and expanded to 85 cases. 72 The potential of ATO to reinforce standard chemotherapy protocols has been investigated in two recently published trials. In a large randomized study of the North American Intergroup, the application of two ATO courses in addition to the ATRA-plus-chemotherapy concept was compared to ATRA plus chemotherapy alone. 73 The other report was a prospective oligocenter, single-arm study, in which the number of chemotherapy cycles was reduced and replaced by one or two cycles Study start with maximum 75 days of ATO. *Consolidation courses mostly consisted of 4-week ATO. **The first consolidation course consisted of 4-week ATO, followed by six maintenance courses of ATO administered for 10 days per month.
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An ongoing randomized study of the French/European APL Group is presently investigating whether ATO can replace Ara-C in low/intermediate-risk patients and whether the combined application of ATO plus Ara-C has influence on the outcome of high-risk patients. 75 Results in newly diagnosed APL. Table 4 shows the results of the prospective studies using ATO for remission induction in frontline therapy. A total of 314 of 362 patients (87%) enrolled in the non-randomized studies achieved CR; 48 deaths (13%) occurred during induction therapy. No resistance was documented. The median time to achieve CR ranged from 30 to 42 days.
The updated Indian study had the longest median follow-up of 60 months and showed a 5-year OS estimate of 74% and a disease-free survival (DFS) estimate of 80%. 71 In the recently updated study by Ghavamzadeh et al. 70 from Iran, the OS estimate was 64% and the DFS was 67%, after a median followup of 38 months. In both trials, the CR rate was 86% and the ED rate 14%, mostly caused by fatal hemorrhages. In the Iranian study, deaths during induction therapy were significantly more frequent in patients with WBC counts higher than 10 Â 10 9 /l (42 versus 6%; P ¼ 0.001). Of note, in the Indian study, no ED was observed in patients with initial WBC counts below 5 Â 10 9 /l. In both of these trials, the median age was approximately 15 years lower, as compared with the studies from Europe and the United States (28 years in the Indian and 29 years in the Iranian study) (Table 3) . 70, 71 In the Iranian study, relapses of patients who remained in CR after 5 years were rare (only one relapse occurred among 36 cases). There was no difference in OS and DSF between patients with lower and higher initial WBC counts than 10 Â 10 9 /l. Importantly, DFS was significantly longer in patients who had received four consolidation courses as compared with only one course (P ¼ 0.03). The fertility was also preserved, as eight female and five male patients with successful reproduction were observed. No secondary malignancies were reported. Forty-four patients with first relapse were treated with ATO again. A second CR was reached in 52% of these patients. The subsequent survival was poor (median: 12 months, 2-year survival: 35%). 70 In the randomized Chinese study, the CR rates in the three treatment arms (ATO monotherapy versus ATO plus ATRA versus ATRA monotherapy, each followed by consolidation and maintenance with chemotherapy) did not differ significantly (90-95%). The overall ED rate was 7% (Table 4 ). The median time to reach CR was shorter in the combined arm (26 days) as compared with ATO alone (31 days) or ATRA alone (41 days). Moreover, the greatest and fastest reduction of PML-RARa transcript levels was induced by the ATO plus ATRA combination. 35 The long-term outcome of the combined arm including 85 patients with a median follow-up of 60 months showed a 5-year OS of 92%, an event-free survival of 89% and relapsefree survival of 95%, thereby confirming a high clinical efficacy of this concept (Table 4) . 72 The results of both ATO-containing US studies in comparison with the European ATRA-plus-chemotherapy studies are shown in Table 6 . In the randomized study of the US Intergroup, a significant advantage of the ATO arm in comparison with the ATRA-plus-chemotherapy arm was seen ( Table 6 ). The 3-year OS, event-free survival and DFS of the combined arm was 86%, 80% and 90%, respectively, which was similar to the results achieved by the ATRA-plus-chemotherapy-containing European protocols. However, it was of note that the 3-year OS (81%), event-free survival (63%) and DFS (70%) estimates of the ATRA-plus-chemotherapy-containing control arm of the US study were relatively low in comparison with the results achieved with the ATRA-plus-chemotherapy regimen reported by others (Table 6) . 73, [76] [77] [78] [79] Therefore, the study of the US Intergroup could not finally clarify a possible beneficial effect of adding ATO to the ATRA-plus-chemotherapy-based regimen. The results of the second US study resemble those of the Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CIR, cumulative incidence of relapse; CR, complete hematological remission; DFS/RFS, disease/relapse free survival; doc. mCR, documented molecular remission; ED, early death (death during induction with ATO); EFS, event free survival; OS, overall survival. Arsenic trioxide in the treatment of acute promyelocytic leukemia E Lengfelder et al
Intergroup study. In that study, a lower cumulative anthracycline dose and a slightly higher Ara-C dose was administered (Tables 5 and 6 ). 74 The results of the first interim analysis of the French/European APL study (APL 2006) suggest that Ara-C can be replaced by ATO without altering the relapse rate in the low/intermediaterisk group. In the treatment protocol for the high-risk group, the combination of Ara-C and ATO increased myelosuppression. 75 Therefore, this study needs further follow-up to asses the final outcome.
Risks and toxicity of ATO treatment
In order to summarize the risks and toxicity of ATO treatment in APL, the studies specified above were screened for the most relevant adverse effects of ATO. Despite of a quick resolution of significant coagulation disturbances after a median of 11 (range 4À28) days of treatment with ATO, 44 severe hemorrhage was the most frequent (70%) cause of EDs. Approximately 80% of these fatal bleeding events were located in the CNS. Half of them occurred within 7 days after the start of therapy.
APL differentiation syndrome was reported in 7À35% of study patients, represented the second most frequent cause of death during induction therapy and was responsible for approximately 15% of the total deaths reported. APL differentiation syndrome generally appeared with hyper-leukocytosis, but was also seen in patients with lower WBC counts. The clinical symptoms of APL differentiation syndrome resembled those of ATRA syndrome such as fever, shortness of breath, weight gain with generalized edema, lung infiltrates without signs of infection, as well as pleural and pericardial effusions, and could be controlled with dexamethasone in most cases. 80 An increase of WBC count was frequently observed accompanying the response to ATO: 32À72% of study patients developed WBC counts above 10 Â 10 9 /l, climbing up to almost 200 Â 10 9 /l within a few days of ATO treatment in some cases. Although spontaneous remission of this leukocytosis has been described, 81 a prophylactic cytoreductive therapy was administered to patients with counts above 10 Â 10 9 /l in most of the studies. Owing to these interventions, additional chemotherapy (for example, hydroxyurea or anthracyclines) was administered in up to 23% of relapsed and up to 85% of newly diagnosed patients in several studies. 45, 71 Apart from these hematological complications, ATO was reported to lengthen the QT/QTc time interval in 63% of the 40 patients included in the US multicenter study. One patient developed a potentially life-threatening cardiac dysrhythmia (ventricular tachycardia of the torsade de pointes type). 44 In the Arsenic trioxide in the treatment of acute promyelocytic leukemia E Lengfelder et al study from Iran, three of 197 (2%) patients died from cardiac arrest or cardiac arrhythmia. 70 Electrolyte imbalances during ATO treatment (hypokalemia, hypomagnesemia) or combination of ATO with drugs that can also lead to QT lengthening (for example, macrolid antibiotics or many psychopharmaceuticals) can increase the probability of cardiac rhythm disorders. These side effects can be prevented by careful monitoring of electrolytes and performing regular ECGs. 26, 42 In the Iranian study, an increase of liver enzymes was observed in 35% of patients. 70 In the Indian study, hepatotoxicity induced by ATO was analyzed in detail. In that study the overall hepatotoxicity was 33%. Grade-3 and 4 hepatotoxicity requiring ATO discontinuation was determined in 7% of the patients. Remarkably, there was a trend of a decreased risk of relapse among patients who developed hepatotoxicity. Moreover, an association of hepatotoxicity with a polymorphism in the MTHFR (methylene tetrahydrofolate reductase) gene was found. Polymorphisms in this gene have been shown to impact the toxicity profile and the metabolism of inorganic arsenic, and might therefore represent a genetic basis for the inter-individual variation in the toxicity profile of ATO. 71 Other undesired effects of ATO treatment were hypokalemia, hyperglycemia, mild peripheral neuropathy, neutropenia, thrombopenia, gastrointestinal disorders, fever, headache and skin rash. In a Chinese study of 20 patients, a reduction of the ATO dose to 0.08 mg/kg/day did not lead to a reduced toxicity profile. 46 
Genetic variants of APL
In rare cases the RARa gene can be fused to other partners than PML, for example, PLZF, STAT5b, NPM, NuMA, owing to alternative genomic translocations. Some of these variants are relatively or completely ATRA-resistant such as t(11;17)(q23; q21) leading to the PLZF-RARa fusion gene, and the fusion gene between STAT5b (mapping close to the RARa locus) and RARa. 3, 82 Other types are ATRA-sensitive such as t(11;17) (q13;q21), t(5;17)(q35;q21) and t(4;17)(q12;q21) leading to the fusion genes NuMA-RARa, NPM1-RARa and FIP1L1-RARa, respectively. [83] [84] [85] The sensitivity of such variants to ATO has not been investigated elaborately. Recently, ATO was shown to be effective in a relapsed case of a NPM-RARa-positive APL, whereas a PLZF-RARa-positive form was shown to be resistant also against ATO. 86, 87 Conclusions and future perspectives ATO is the most active single agent available for therapy of APL and represents an efficient treatment option for all stages and age groups of APL. 88, 89 For relapsed APL, ATO is currently regarded as the therapeutic agent of choice. In a comparison of an ATRA-pluschemotherapy-based salvage regimen to such containing ATO, treatment with ATO has the advantage of considerably less toxicity. A historical comparison of French data shows a clear survival advantage with ATO-based relapse therapy as compared with ATRA and chemotherapy (77 versus 51% after 2 years). This was particularly attributed to the favorable toxicity profile of ATO, which enabled higher rates of transplantation and a reduction of transplantation-associated mortality. 54 Patients, who receive induction and consolidation therapy with ATO in relapse after first-line therapy with ATRA and chemotherapy, have a good chance to achieve a stable second remission and possible cure. There is some evidence from non-comparative studies that continuation of ATO treatment may improve outcome as compared with applying no further therapy. Efficient approaches to maintain remissions after consolidation include prolonged application of ATO cycles (±ATRA), conventional chemotherapy (±ATRA) and autologous or allogeneic stem cell transplantation, as well as a maintenance therapy with a combination of ATO, ATRA and/or low-dose chemotherapy.
Before the introduction of ATO, autologous transplantation after salvage therapy with intensive chemotherapy was shown to induce stable long-term remissions and possible cure, provided the transplantation was performed in molecular remission with PCR-negative stem cells. 11, 90 This is also true for autologous transplantation after ATO-based salvage therapy, which has the advantage of less toxicity compared with chemotherapy. 54, 60 Owing to a high treatmentassociated mortality and toxicity of allogeneic transplantation, this approach should probably be reserved for high-risk situations, such as second or later relapse, molecular persistence or early relapse after frontline therapy. 11, 91, 92 As controlled comparisons of the options for post-remission therapy are lacking, the choice of treatment should be adapted individually to each patient.
Concerning the timing of salvage therapy with ATO, an early treatment of imminent relapse seems to be advantageous. Preliminary results of the European Registry for Relapsed APL (PROMYSE) suggest a lower risk of bleeding and APL differentiation syndrome when treatment is started in molecular relapse as compared with full clinical relapse. 93 In a study conducted by the British MRC performing serial MRD monitoring, the rate of clinical relapse could be reduced by the introduction of a pre-emptive ATO therapy initiated according to molecular relapse as compared with a historical control in which MRD monitoring and pre-emptive therapy were not routinely undertaken. 94 According to these data, early treatment of molecular relapse seems beneficial.
The high anti-leukemic efficacy and the favorable toxicity profile of ATO were also shown in newly diagnosed APL, as high remission and cure rates could even be induced with ATO alone without the additional application of chemotherapy. The preservation of fertility and the possible avoidance of secondary malignancies are important long-term aspects in the context of the high curability of APL.
The results of studies combining ATO and chemotherapy or gemtuzumab ozogamicin seem similar to those with ATRA and chemotherapy (Tables 4 and 6) , and indicate that chemotherapy can be reduced or even eliminated when ATO is incorporated (Tables 3 and 5) . 68, 69, [73] [74] [75] The high rate of EDs among APL patients is still a great problem in APL therapy. Independently of the administered antileukemic therapy, it remains a challenge to manage the potentially life-threatening risks in the early treatment phase especially in patients presenting with high WBC counts, coagulation disorders or APL differentiation syndrome. Moreover, in recent reports from Europe and the United States, it was shown that a considerable part of APL patients are probably not included into clinical trials owing to poor condition or death before the start of therapy. [95] [96] [97] This suggests that the group of APL patients included in clinical trials may represent a favorable selection and therefore cause an overestimation of the true outcome of APL. Therefore, the relatively high ED rates of approximately 14% as reported in the Indian and Iranian study may be difficult to compare with the ATRA-plus-chemotherapybased studies.
Concerning the risk of relapse, further studies with ATO in frontline therapy of APL might allow to determine whether the commonly used risk score generated from studies with ATRA-and anthracycline-based therapy is applicable to patient cohorts treated with ATO. 98 Presently, ATO is only approved for treatment of relapsed APL in Europe and the United States. Therefore, in newly diagnosed APL the use of ATO should be restricted to patients enrolled in clinical trials or to patients who have contraindications against chemotherapy.
In summary, a wealth of data corroborates a high efficacy and favorable toxicity profile of ATO in APL therapy, which merits further efforts in experimental research and clinical trials to optimize future APL therapy with ATO.
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